

Mag One Products Inc.

CSE: MDD
FSE & Xetra: 304, Equity
OTCQB: MgPRF

For Immediate Release

Mag One Products' Progress Report and New Team Member

VANCOUVER, BRITISH COLUMBIA, CANADA/17 MAY 2016. [CSE:MDD FSE & Xetra:304-Equity, OTCQB:MgPRF]


MAG ONE PRODUCTS INC. ("Mag One" or the "Company") has a program underway to produce 99.9% pure magnesium ("Mg") metal, high-purity Mg compounds, and byproducts from its extensive supply of serpentine-rich mine tailings (~23% Mg) located near Danville, Quebec, Canada.



MAGNESIUM:

Originally, Mag One's cost of the tailings was \$1.50/tonne. However, the supplier, Mine Jeffrey, has now agreed as of May 13, 2016, to reduce this cost to \$1.00/tonne, a savings of \$15,000,000.00, provided the Company starts production by January 01, 2017. Accordingly, Mag One's target is to be producing >98% pure MgO on or before January 01, 2017. Note that this MgO production is a precursor to the Company's ultimate aim of production of Mg metal.

Mag One is also pleased to report that its first 10,000 tonne/annum, environmentally benign (CO₂- and chlorine-free), modular manufacturing plant (to convert the tailings to high-purity MgO and Mg(OH)₂) is now in an advanced stage of design. Selected pieces of processing equipment for the plant are being sourced in preparation for commencing operations this fall/winter.




Recently, independent laboratory measurements in Quebec have provided key supporting evidence for Mag One's MgO/Mg(OH)₂ production process concept. Details of the test results will be released by Mag One after completion of two patent applications.

LITHIUM:

Further, the Company hereby announces that Dr. Jagmohan Singh—formerly with the renowned Oak Ridge National Laboratory (ORNL) in Oak Ridge, TN, USA—has been hired to provide key technical assistance to Dr. Jim Blencoe in Mag One's work to bring the Mg concept to

commercialization. Dr. Singh's mandate is to help advance Mag One's innovative, proprietary, modular MgO/Mg(OH)₂/Mg production concept, and in parallel, to work closely with Dr. Blencoe to develop similar modular production methods for manufacturing **lithium hydroxide, LiOH, and lithium carbonate, Li₂CO₃, from spodumene, LiAlSi₂O₆**. It should be noted that Dr. Blencoe already has experience with lithium, having been part of a lithium-production patent application team while at ORNL.



Signed:

"Nelson M. Skalbania", B.Ap.Sc., M.Sc., P.Eng.
Chairman

For further information or questions kindly contact the Company via email: info@MagOneProducts.com
#145 925 Georgia Street West, Vancouver, B.C. CANADA V6C3L2 T: +1.604.669.4771 F: +1.604.669.4731

www.MagOneProducts.com

Mag One is co-listed on the Börse Frankfurt stock exchange ("FSE") and the Xetra, both with the ticker symbol "304" and the OTCQB with ticker symbol "MgPRF". The listings on the Frankfurt and OTCQB exchanges provide the company exposure to the European and U.S. markets and investors. Certain statements contained in this release may constitute "forward-looking statements" or "forward-looking information" (collectively "forward-looking information") as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated", "anticipates" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, the Property, financing and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein. These securities have not and will not be registered under United States federal or state securities laws and may not be offered or sold in the United States or to a U.S. Person unless so registered, or an exemption from registration is relied upon. This news release does not constitute an offer of securities for sale in the United States. CSE has not reviewed this news release and does not accept responsibility for the adequacy or accuracy of the content of this news release. The above news release has been provided by the above company via the OTC Disclosure and News Service and The Newswire. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.